KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Edwards Lifesciences (EW) Debt to Equity (2016 - 2025)

Edwards Lifesciences has reported Debt to Equity over the past 17 years, most recently at $0.06 for Q4 2025.

  • Quarterly results put Debt to Equity at $0.06 for Q4 2025, down 2.56% from a year ago — trailing twelve months through Dec 2025 was $0.06 (down 2.56% YoY), and the annual figure for FY2025 was $0.06, down 2.56%.
  • Debt to Equity for Q4 2025 was $0.06 at Edwards Lifesciences, down from $0.06 in the prior quarter.
  • Over the last five years, Debt to Equity for EW hit a ceiling of $0.13 in Q1 2021 and a floor of $0.06 in Q2 2025.
  • Median Debt to Equity over the past 5 years was $0.09 (2023), compared with a mean of $0.09.
  • Biggest five-year swings in Debt to Equity: grew 0.6% in 2022 and later tumbled 33.15% in 2024.
  • Edwards Lifesciences' Debt to Equity stood at $0.1 in 2021, then grew by 0.6% to $0.1 in 2022, then fell by 13.48% to $0.09 in 2023, then tumbled by 33.15% to $0.06 in 2024, then dropped by 2.56% to $0.06 in 2025.
  • The last three reported values for Debt to Equity were $0.06 (Q4 2025), $0.06 (Q3 2025), and $0.06 (Q2 2025) per Business Quant data.